Life Sciences

  • Microbiome / Nutrition / Foodtech / Lifestyle
  • Medtech / Connected health / Digital health
  • Biotech & pharmaceuticals
  • Industrial Biotech & Cleantech
  • Animal health / Animal Feed & Nutrition

Read more

Digital Technologies

  • Fintech
  • Retailtech
  • Other digital innovative solutions
  • Hardware & telecom

Read more

Sport & Performance Capital

  • Sport-Health
  • Equipment
  • Food-Nutrition
  • IOT-Digital
  • Sports practice

Read more

Blue Economy

  • Sustainable aquaculture
  • Nutrition Cosmetics Health
  • Industrial Products & Biomaterials
  • Biopolymers and biopackaging
  • Digitalization Blue 3.0
  • Recycling, Bioremediation
  • Climate & Carbon
  • Bioenergies, hydrogen

Read more

News

  • Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
    16 October 2025

    Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463

    Enterome, a clinical-stage company developing...

  • Sunrise Group: $29 Million Raised For Expanding Dreem Health
    1 October 2025

    Sunrise Group: $29 Million Raised For Expanding Dreem Health

    Sunrise Group, known as a leader in sleep health...

  • With a €860,000 investment, Seventure Partners joins Kapsera’s funding round, raising its Series A to €5 million.
    22 September 2025

    With a €860,000 investment, Seventure Partners joins Kapsera’s funding round, raising its Series A to €5 million.

    Kapsera, a pioneer in sustainable microencapsulation for...

  • First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis
    2 September 2025

    First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis

    Citryll, a biotech company pioneering a transformative...

  • Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
    23 June 2025

    Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

    60% (12/20) complete response rate after treatment with...